Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors

NCT01724320 is registered in ClinicalTrials.gov with Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) as lead sponsor.

NCT NCT01724320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01724320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors
Lead sponsor
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase
Phase 1
Overall status
Unknown status
Start date
February 29, 2012
Completion date
May 31, 2013
Enrollment
20 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors